Engel J, Lazar N
Direct Meds tiers by dose, which is cheaper for starter doses (around $200 to $250) and comparable or slightly cheaper at maintenance (around $300 to $400)
95% CI, 0.630.85), with no significant interaction by sex ( Regarding safety, women experienced a higher incidence of genital infections while on SGLT-2 inhibitors, likely due to anatomical predisposition, which may impact treatment adherence ( For GLP-1 receptor agonists, the REWIND trial demonstrated a reduction in cardiovascular events with dulaglutide, with a trend toward greater benefit in women, although statistical significance was not achieved (RR 0.85
Phase 3 clinical trials have shown promising weight loss results, and if approved, orforglipron could become the first truly effective oral option in this drug class
Clinician qualifications and obesity medicine expertise Only [fewer than 8,300 physicians]( in the United States are board-certified in obesity medicine to treat people with overweight or obesity